## CITATION REPORT List of articles citing

A clinical and economic review of disease-modifying antirheumatic drugs

DOI: 10.2165/00019053-200119070-00002 Pharmacoeconomics, 2001, 19, 715-28.

Source: https://exaly.com/paper-pdf/32514166/citation-report.pdf

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
33	Management of Rheumatoid Arthritis. <i>Disease Management and Health Outcomes</i> , <b>2002</b> , 10, 17-39		5
32	Pharmacoeconomics of long-term treatment of rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2002</b> , 3, 417-22	4	2
31	Start DMARDs early in patients with rheumatoid arthritis. <i>Drugs and Therapy Perspectives</i> , <b>2002</b> , 18, 3-7	1.5	
30	Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. <i>BioDrugs</i> , <b>2002</b> , 16, 111-48	7.9	71
29	Metals. Side Effects of Drugs Annual, <b>2003</b> , 26, 243-252	0.2	
28	Review of health economics modelling in rheumatoid arthritis. <i>Pharmacoeconomics</i> , <b>2004</b> , 22, 55-69	4.4	18
27	Dosing Patterns of Anti-TNF Therapy in Patients with Rheumatoid Arthritis in a Managed Care Setting. <i>Disease Management and Health Outcomes</i> , <b>2004</b> , 12, 189-196		1
26	Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. <i>Rheumatology</i> , <b>2005</b> , 44, 1169-75	3.9	81
25	Effects of azathioprine and its metabolites on repair mechanisms of the intestinal epithelium in vitro. <i>Regulatory Peptides</i> , <b>2005</b> , 131, 1-11		23
24	Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. <i>Drugs</i> , <b>2005</b> , 65, 661-94	12.1	77
23	Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. <i>Drugs</i> , <b>2005</b> , 65, 2179-208	12.1	63
22	International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. <i>Pharmacoeconomics</i> , <b>2005</b> , 23, 243-57	4.4	26
21	The role of antimalarials in the exacerbation of psoriasis: a systematic review. <i>American Journal of Clinical Dermatology</i> , <b>2006</b> , 7, 249-57	7.1	12
20	Health economic issues in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2006, 35, 415-25	1.9	30
19	Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?. <i>Biomedicine and Pharmacotherapy</i> , <b>2006</b> , 60, 688-92	7.5	15
18	Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis. <i>Rheumatology International</i> , <b>2007</b> , 27, 1063-9	3.6	8
17	Actualit`sur la maladie, cots et qualit`de vie des patients atteints de polyarthrite rhumatotie en France´: tude ECO-PR. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2008</b> , 75, 804-812	0.1	4

## CITATION REPORT

16	Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. <i>Joint Bone Spine</i> , <b>2008</b> , 75, 408-15	2.9	63
15	Poor reporting of search strategy and conflict of interest in over 250 narrative and systematic reviews of two biologic agents in arthritis: a systematic review. <i>Journal of Clinical Epidemiology</i> , <b>2009</b> , 62, 128-37	5.7	25
14	Pharmacologically active metabolites of currently marketed drugs: potential resources for new drug discovery and development. <i>Yakugaku Zasshi</i> , <b>2010</b> , 130, 1325-37	Ο	19
13	Functional capacity in rheumatoid arthritis patients: comparison between Spanish and Brazilian sample. <i>Rheumatology International</i> , <b>2011</b> , 31, 221-6	3.6	8
12	Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature. <i>International Journal of Rheumatology</i> , <b>2011</b> , 2011, 845496	2	26
11	Gold and gold salts. <b>2016</b> , 572-583		
10	Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 460	5.6	162
9	Turkish League Against Rheumatism (TLAR) Recommendations for the Pharmacological Management of Rheumatoid Arthritis: 2018 Update Under Guidance of Current Recommendations. <i>Archives of Rheumatology</i> , <b>2018</b> , 33, 251-271	0.9	1
8	Natural Formulations: Novel Viewpoint for Scleroderma Adjunct Treatment. <i>Journal of Immunology Research</i> , <b>2021</b> , 2021, 9920416	4.5	
7	Targeting DMARD therapy. <b>2005</b> , 25-47		
6	Gold and gold salts. <b>2006</b> , 1520-1529		
5	Other Traditional Disease-Modifying Antirheumatic Drugs: Monotherapy and Combination Therapy. <b>2009</b> , 325-336		
4	Vaccines and Biologically Produced Pharmaceuticals. <b>2009</b> , 93-110		
3	GLUCOCORTICOIDS AND DISEASE [MODIFYING ANTIRHEUMATIC DRUGS. <b>2010</b> , 371-667		
2	Marine-derived microbes and molecules for drug discovery. <i>Inflammation and Regeneration</i> , <b>2022</b> , 42,	10.9	O
1	Rotator Cuff Repair in Patients with Inflammatory Arthritis: Satisfactory Mid-Term Outcomes. <b>2022</b> ,		O